DEPARTMENT OF HEALTH AND HUMAN SERVICES 
NATIONAL INSTITUTES OF HEALTH 
RECOMBINANT DNA ADVISORY COMMITTEE 
MINUTES OF MEETING 1 
December 1-2, 1994 
The Recombinant DNA Advisory Committee (RAC) was convened for its sixtieth meeting at 9:00 a.m. on 
December 1, 1994, at the National Institutes of Health, Building 31, Conference Room 6, 9000 Rockville Pike, 
Bethesda, Maryland 20892. Dr. LeRoy B. Walters (Chair) presided. In accordance with Public Law 92-463, 
the meeting was open to the public on December 1 from 9 a.m. until 5 p.m. and December 2 from 8:30 a.m. 
until 3:50 p.m. The following were present for all or part of the meeting: 
Committee Members: 
Constance E. Brinckerhoff, Dartmouth Medical School 
Alexander M. Capron, University of Southern California 
Gary A. Chase, Georgetown University Medical Center 
Patricia A. DeLeon, University of Delaware 
Roy H. Doi, University of California, Davis 
Robert P. Erickson, University of Arizona 
Joseph C. Glorioso, University of Pittsburgh 
Robert Haselkom, University of Chicago 
Abbey S. Meyers, National Organization for Rare Disorders 
A. Dusty Miller, Fred Hutchinson Cancer Research Center 
Arno G. Motulsky, University of Washington 
Robertson Par km an, Children’s Hospital of Los Angeles 
Gail S. Ross, Cornell University Medical Center 
Bratin K. Saha, Emory University 
R. Jude Samulski, University of North Carolina 
Marian G. Secundy, Howard University College of Medicine 
Brian R. Smith, Yale University School of Medicine 
Stephen E. Straus, National Institutes of Health 
LeRoy B. Walters, Kennedy Institute of Ethics, Georgetown University 
Doris T. Zallen, Virginia Polytechnic Institute & State University 
Executive Secretary: 
Nelson A. Wivel, National Institutes of Health 
A committee roster is attached (Attachment I). 
Liaison Representative: 
Barbara Levin, National Institute of Standards and Technology, Department of Commerce 
National Institutes of Health staff: 
Bobbi Bennett, OD 
Diane Bronzert, NCI 
Kenneth Cowan, NCI 
Barry Goldspiel, CC 
*rhe RAC is advisory to the National Institutes of Health (NIH), and its 
recommendations should not be considered as final or accepted. The Office of 
Recombinant DNA Activities should be consulted for NIH policy on specific issues. 
Recombinant DNA Research, Volume 20 
[430] 
